AUTL
Autolus Therapeutics plc
There isn't enough reported data to score AUTL yet.
AUTL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
AUTL's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
AUTL PE Valuation
AUTL has no meaningful PE right now: it lost money over the past year.
AUTL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect AUTL's losses to shrink, with revenue growing.
AUTL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.97 | -$0.14 |
| Q2 2026 | -$1.06 | -$0.22 |
| Q1 2026 | -$1.09 | -$0.21 |
| Q4 2025 | -$1.08 | -$0.22 |
| Q3 2025 | -$0.83 | +$0.39 |
| Q2 2025 | -$0.84 | +$0.33 |
| Q1 2025 | -$0.88 | +$0.33 |
| Q4 2024 | -$0.86 | +$0.34 |
AUTL is still losing money, but far less than before: $0.97 per share over the past year, against $2.77 at its worst in late 2019.
AUTL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $41.2M | +95% |
| Q2 2026 | $45.7M | +118% |
| Q1 2026 | $26.2M | +192% |
| Q4 2022 | $3.8M | +2025% |
| Q3 2022 | $2.4M | +904% |
| Q4 2021 | $180K | -55% |
| Q3 2021 | $236K | -65% |
| Q2 2021 | $1.6M | +461% |
AUTL's revenue has grown year over year for seven quarters in a row: $41M last quarter, up 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -106% | +232 points |
| Q2 2026 | -96% | +197 points |
| Q1 2026 | -227% | +499 points |
| Q4 2025 | -298% | N/A |
| Q3 2025 | -338% | N/A |
| Q2 2025 | -293% | N/A |
| Q1 2025 | -726% | N/A |
| Q1 2023 | -2738% | N/A |
AUTL's operating margin was −106% last quarter, up 232 points from the same quarter a year ago.
AUTL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.8M | +$52.5M |
| Q2 2026 | -$26M | +$54.1M |
| Q1 2026 | -$68M | +$15.8M |
| Q4 2025 | -$66.4M | -$17.4M |
| Q3 2025 | -$72.3M | +$14M |
| Q2 2025 | -$80.1M | -$28.1M |
| Q1 2025 | -$83.8M | -$42.8M |
| Q4 2024 | -$49M | -$22.7M |
AUTL has burned cash in almost every quarter: −$180M over the past year, against −$285M the year before.
AUTL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +44.8K shares |
| 1 year | 0% | +62.2K shares |
| 3 years | +53% | +92.3M shares |
| 5 years | +276% | +195M shares |
| Available history | +434% | +216M shares |
AUTL has 266M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
AUTL Net Leverage
AUTL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AUTL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.0 | Neutral |
| Stochastic | 6.1 | Oversold |
AUTL's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
AUTL PE vs Healthcare Sector
AUTL has no meaningful PE right now: it lost money over the past year.
AUTL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.57 | 24% below |
| 20 week MA | $1.76 | 32% below |
| 50 week MA | $1.63 | 27% below |
| 100 week MA | $1.73 | 31% below |
| 200 week MA | $2.71 | 56% below |
AUTL is in a downtrend: it's below all five of its weekly moving averages, and 56% below its 200-week average.
AUTL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.6 | $8.90 | -35% |
| 2021 | $8.90 | $5.46 | -39% |
| 2022 | $5.46 | $1.86 | -66% |
| 2023 | $1.86 | $6.44 | +246% |
| 2024 | $6.44 | $2.26 | -65% |
| 2025 | $2.26 | $1.67 | -26% |
| 2026 YTD | $1.67 | $1.19 | -29% |
AUTL's yearly returns have swung widely, from +246% in 2023 to −66% in 2022. It's down 29% so far in 2026.